Weekly roundup: A successful fundraising for One Biosciences, the Novo Nordisk Foundation’s acquisition of the world’s most powerful quantum computer, Xeltis’ positive data for Xabg, and Optimum TV’s launch of its ‘Thought Leaders’ series
One Biosciences announces €15 Million Series A financing to advance clinical single cell profiling
One Biosciences, a precision oncology techbio company pioneering clinical grade single-cell tumour transcriptomic profiling, announced a €15 million Series A financing led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures.
The funding will be used to establish the clinical utility of OneMap™, a proprietary artificial intelligence (AI) driven single cell transcriptomic oncology platform, to guide treatment decisions, patient selection, therapy development, and optimise clinical trials.
EIFO and the Novo Nordisk Foundation acquire the world’s most powerful quantum computer
The Novo Nordisk Foundation, an independent Danish enterprise foundation, and EIFO, the export and investment fund of Denmark, are investing €80 million in the establishment of a new Nordic quantum initiative, QuNorth, to advance the region’s technological development. Microsoft and Atom Computing will bring the world’s most powerful quantum computer, and the first operational deployment of a machine powered by logical qubits, to QuNorth.
Xeltis announces positive data for Xabg, its coronary artery bypass conduit
Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announced encouraging preliminary data for Xabg, its coronary artery bypass conduit (CABG), demonstrating positive safety and patency among patients with multi-vessel atherosclerotic coronary artery disease. This underscores the potential of Xabg to eliminate the need for vein harvesting and transform the bypass surgery landscape with the goal of longer-term durability. In an earlier, separate trial, Xabg recently demonstrated patency with excellent flow in a 24-month trial – the first time ever this duration has been achieved.
📺Optimum TV
The first instalment of Optimum TV’s ‘Thought Leaders’ series features renowned biopharma journalist Melanie Senior. The episode focuses on Melanie’s latest article for Nature Biotechnology, ‘Biotech Financing: Divide and Reset’. Melanie discusses the main take-outs of her in-depth piece, including how the difficult financing environment has led to a winner takes all situation, what’s popular right now among investors (and what isn’t), and the swift rise of China as a major force in biotech innovation. Watch the full episode below.
🔥Hot topic
With the patent cliff looming closer, Big Pharma firms need to replace the billions of revenues that their current blockbusters make them – which will soon be undercut by cheaper generics and biosimilars. In this week’s Hot Topic, Optimum’s Stephen Adams dives into how they are looking to future-proof their pipelines and asks, ‘Are they missing a trick?’ Read the full article here.
👥Industry events
Optimum’s 17th Annual Healthcare Conference
Returning to The King’s Fund this autumn, this prestigious invitation-only event brings together investors and executives from across the life sciences sector, register your interest in attending today.
📍Thursday 9th October, London
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
